Navigation Links
Confirmation of HGT Business Day - 18th November 2008
Date:11/12/2008

LEXINGTON, Massachusetts, November 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is holding an update on its Human Genetic Therapies (HGT) business for analysts and investors on 18th November 2008.

The seminar will include both an overview of Shire's overall HGT strategy and an in-depth look at the portfolio of HGT products both on the market and in development. The session will start at 9.00am (ET) and will finish at 2.30pm (ET). It is being held at Shire's HGT offices in Lexington, Massachusetts and will be webcast at http://www.shire.com. The seminar will not be providing an update on current trading. Further information on the seminar will be available on the Company's website, http://www.shire.com.

Presentations will be made by Angus Russell, Shire's Chief Executive, Sylvie Gregoire, President of Shire HGT and her senior team. In addition, Shire is pleased to announce that Pr. Marco Cicardi, M.D. University of Milan and Specialist in Angioedema will present on Hereditary Angioedema.

Notes to editors

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shi
'/>"/>

SOURCE Shire Plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
2. Confirmation of Strong Growth Over the First Half of 2008
3. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
4. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
8. ThromboGenics N.V.: Business Update
9. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
10. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... in German . , Whether it,s CD packaging, c...o Frequency Identification) are increasingly findi...ible to label objects or goods and identify them a...canner can read and process the data contained in ...der production conditions of up to 100 degrees Cel...
(Date:11/24/2009)...HEIM, Ontario, Nov. 24 D...ring the assets of Hyland Seeds, a division of Tho...of Hyland Seeds will further expand Dow AgroScienc...tes the introduction of SmartStax(TM) in 2010 ...chnology in corn in 2012. The transactional close ...
(Date:11/24/2009)... Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceuticals ...e (PTO) has allowed the patent application for,its..., NOD technology is a highly efficient appr...adhesive nano-particles to enable oral delivery of...echnology is a platform technology,that can be app...
(Date:11/24/2009)...ficacy endpoint has been met for patients with adv...,, QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ ... (the "Company"), a global biopharmaceutical compa...y announced positive efficacy data from a Phase 2 ...e, AEZS-108 (formerly AN-152), in patients with ad...
Breaking Biology Technology:Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...s Miller, CEO Workflow and Solutions Division, Sie...vent Keynote Speaker, PHILADELPHIA, Jan. 28 Rece...molecular imaging, molecular diagnostics,and infor...ls capable of,assessing and treating a growing num...ls provide physicians with an understanding of ind...
...AIN VIEW, Calif., Jan. 28 Clontech Laboratories,I... today announced the,imminent (February 20, 2008) ...featured in the April issue of Clontechniques, the...researchers at Stanford University and,licensed fr...technology to,regulate the amount of protein of in...
..., Pa., Jan. 28 BioTrends Research Group, Inc.,rel... Publication, a,syndicated report offering compreh... and bone and mineral metabolism in Chronic Kidney...o an online survey, completed by,305 clinical neph...e anemia market, the vast majority of nephrologist...
Other Biology Technology:The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 2The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 3The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 4Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems 2BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2
(Date:11/24/2009)...ies from collapsing have been true life-savers. Bu...ded -- once the arteries are strengthened, they be...e but to leave them in place. , Prof. Meital Zil...edical Engineering has developed a new patent-pend...e needed, then dissolves. , "Our new composite f...
(Date:11/24/2009)...9) -- The Wildlife Conservation Society (WCS) anno...ning population of Siberian tigers has likely decl...ing and habitat loss. , WCS says the... needs to be done to protect remaining populations...report was released by the Siberian Tiger Monitori...
(Date:11/24/2009)...search on bacterial communities throughout six lar...poral patterns, suggesting that scientists could u...mate change in the polar regions. The study, publi... Academy of Sciences Early Edition, shows that ba...hronously over time, correlating with seasonal shi...
Breaking Biology News(10 mins):A coating for life 2Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 1Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 2Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 3Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 4Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 5Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 6Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 1Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 2Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 3Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 4HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 1HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 2HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 3
... lowly sea slug, "Elysia chlorotica," may not seem... fooled: it behaves like a plant and is solar-powe... been studying these tiny creatures for the past d...niversities, has identified a possible cause of th...sor James Manhart is a member of a research group ...
...hose who consume fewer calories during flu season ...s, according to research by Michigan State Univers...dner. , In a study published in the November issu...at mice with a calorie-restricted diet were more l...n than mice with a normal diet. Caloric restrictio...
...nanced by NWO, has discovered a new mechanism for ...y hot and acidic conditions. The results of the re...o the functioning of the human body. The research ...e of the American National Academy of Sciences. Th... a Rubicon grant from NWO in 2006 to gain experien...
Other Biology News:Solar-powered sea-slugs live like plants, prof says 2Feed a cold, feed a fever: Research shows calorie cut makes it harder to fight flu 2Proteins strangle cell during division 2
Giemsa stain from Sigma-Aldrich
Bovine Serum, Sterile Filtered from Meridian Life Science, Inc.
CORNING IVF CULTURE DISH, 60 X 15MM, PS, STERILE from Sigma-Aldrich
LV-2080 Solvent Switching Valve from JASCO
Biology Products: